Spots Global Cancer Trial Database for Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Toripalimab Plus FLOT in Locally Advanced Gastric Cancer

Official Title: Toripalimab Combined With FLOT Regimen in Locally Advanced Gastric cancer-a Prospective, Open, Single-center, Phase Ⅱ Clinical Study

Study ID: NCT04891016

Conditions

Chemotherapy

Immune Checkpoint Inhibitor

Locally Advanced Gastric Carcinoma

Interventions

delayed toripalimab

control

Study Description

Brief Summary: Neoadjuvant therapy for locally advanced gastric cancer is still in the exploratory stage. With the emergence of immune checkpoint inhibitors, neoadjuvant chemoimmunotherapy is also in the exploratory stage in locally advanced gastric cancer. At present, chemotherapy combined with immunotherapy is usually a simple combination of chemotherapeutic drugs and immune drugs, without taking into account of the influenece of applied sequence. The purpose of this study is to explore whether the sequence of chemotherapy and immunotherapy influence the complete pathological response rate in locally advanced gastric cancer.

Detailed Description: Neoadjuvant therapy for locally advanced gastric cancer is still in the exploratory stage. With the emergence of immune checkpoint inhibitors, neoadjuvant chemoimmunotherapy is also in the exploratory stage in locally advanced gastric cancer. At present, chemotherapy combined with immunotherapy is usually a simple combination of chemotherapeutic drugs and immune drugs, without taking into account of the influenece of applied sequence. The purpose of this study is to explore whether the sequence of chemotherapy and immunotherapy influence the complete pathological response rate in locally advanced gastric cancer. All patients received toripalimab plus FLOT regimen. If pCR was achieved, the patients received two cycles of toripalimab plus FLOT, then toripalimab maintenance until one year, if pCR was not achieved, the patients received 8 cycles of perioperative toripalimab plus FLOT, then toripalimab maintenance until one year.